Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence
University of California, Los Angeles (UCLA), Health SciencesA new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.